FDA allows marketing for Affymetrix CytoScan Dx Assay

|By:, SA News Editor

The FDA clears a first-of-a-kind blood test, developed by Affymetrix (AFFX -0.3%), that can help predict intellectual disabilities in infants by analyzing their genetic code.

The CytoScan Dx Assay test detects variations in patients' chromosomes that are linked to Down syndrome, DiGeorge syndrome and other developmental disorders.